Clinical Trial Results:
Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.
Summary
|
|
EudraCT number |
2016-002680-34 |
Trial protocol |
ES |
Global end of trial date |
28 Nov 2018
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Nov 2021
|
First version publication date |
24 Nov 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
DEXPAR
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02982512 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Clinica Universidad de Navarra
|
||
Sponsor organisation address |
AVENIDA PÍO XII, Nº 36, PAMPLONA/IRUÑA, Spain, 31008
|
||
Public contact |
UCEC, Clinica Universidad de Navarra, 34 948 255 400, ucicec@unav.es
|
||
Scientific contact |
UCEC, Clinica Universidad de Navarra, 34 948 255 400, ucicec@unav.es
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
31 Jan 2020
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
28 Nov 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Nov 2018
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To study and quantify the possible effect of different doses of dexmedetomidine (0.2-0.6 µg/kg/h) on the local field potentials (deep brain activity) in patients with Parkinson´s disease undergoing deep brain stimulation implantion.
|
||
Protection of trial subjects |
NA
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
03 Oct 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 12
|
||
Worldwide total number of subjects |
12
|
||
EEA total number of subjects |
12
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
8
|
||
From 65 to 84 years |
4
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Patients, of legal age, undergoing DBS placement for Parkinson's disease (NST or GPi) in two stages. | ||||||
Pre-assignment
|
|||||||
Screening details |
14 patients agreed to participate in the trial, but eventually only 12 patients were exposed to the study drug. | ||||||
Period 1
|
|||||||
Period 1 title |
Treatment period (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Treatment | ||||||
Arm description |
No Intervention: Control recording Recording of local field potentials without drugs from the deep brain stimulator Experimental: Dexmedetomodine recording Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator Intervention: Drug: Dexmedetomidine | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
DEXMEDETOMIDINE
|
||||||
Investigational medicinal product code |
|||||||
Other name |
(S)-4-[1-(2,3-Dimethylphenyl)ethyl]-3H-imidazole
|
||||||
Pharmaceutical forms |
Concentrate for solution for infusion
|
||||||
Routes of administration |
Intravenous use
|
||||||
Dosage and administration details |
The administration of the drug will be carried out in a single session for 3 hours and 55 minutes. A loading dose of the drug will be administered (0.5 μg / kg in 10 min) and increasing doses of 0.2, 0.3, 0.4, 0.5 and 0.6 μg / kg / h spaced in periods of time of 45 min.
|
||||||
|
|
|||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
Treatment period
|
||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Treatment
|
||
Reporting group description |
No Intervention: Control recording Recording of local field potentials without drugs from the deep brain stimulator Experimental: Dexmedetomodine recording Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator Intervention: Drug: Dexmedetomidine |
|
|||||||||
End point title |
Changes in neuronal activity. Dexmedetomidine. [1] | ||||||||
End point description |
A loading dose of the drug will be administered (0.5 μg / kg in 10 min) and increasing doses of 0.2, 0.3, 0.4, 0.5 and 0.6 μg / kg / h spaced in periods of time of 45 min.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
The administration of the drug will be carried out in a single session for 3 hours and 55 minutes.
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: With dexmedetomidine infusion, patients became clinically sedated, and at higher doses (0.5-0.6 mg/kg/h) a significant decrease in the characteristic Parkinsonian subthalamic activity was observed (P<0.05 in beta activity). All subjects awoke to external stimulus over a median of 1 (range: 0e9) min, showing full restoration of subthalamic activity. Dexmedetomidine dose administered and plasma levels showed a positive correlation (repeated measures correlation coefficient¼0.504; P<0.001). |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
Adverse events are collected from the time the patient is treated until the end of their follow-up.
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
ND | ||
Dictionary version |
ND
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No adverse events were reported. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |